Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants
Status:
Active, not recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
Study Hypothesis: Preterm infants administered weekly Darbe during the neonatal period will
have improved neurocognitive outcome at 22-26 months compared to placebo